Introduction {#S0001}
============

Adequate adherence to antiretroviral therapy (ART) is critical to successful HIV treatment. Discontinuation or the lack of consistent long-term adherence to ART can lead to drug resistance, AIDS-related illnesses and death, and can increase the risk of forward transmission \[[@CIT0001]--[@CIT0003]\]. As low rates of adherence have been reported in both high-income and low-income settings \[[@CIT0004]\], achieving and maintaining high rates of ART is a global concern.

Recent enthusiasm has explored the use of peers in improving the adherence to ART. Given that most high HIV prevalence settings have limited resources and stigma plays an important role in adherence, peer-based interventions may be a practical solution. However, the effectiveness of peer-based interventions is currently unclear. Peer-based interventions have demonstrated some success in supporting patient adherence, but most studies come from high-income countries with varying study quality \[[@CIT0005]\]. More recent systematic reviews exploring different interventions for adherence have been limited to Africa, and their focus has not differentiated peer-based interventions \[[@CIT0006], [@CIT0007]\]. Therefore, it is important to evaluate the effectiveness of peer-based interventions using the global scope of evidence.

We aimed to determine whether using peers to provide adherence support and counselling results in better adherence to ART compared to the standard-of-care (SOC). We used a network meta-analysis (NMA) approach that draws from both direct and indirect evidences to estimate the comparative effects because HIV adherence research has few head-to-head comparison trials. Our findings from this study were recently used to inform the latest iteration of the World Health Organization (WHO)\'s global consolidated guidelines for HIV \[[@CIT0008]\].

Methods {#S0002}
=======

Search strategy and selection criteria {#S0002-S20001}
--------------------------------------

Our analysis and report was designed and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) extension to NMA \[[@CIT0009]\]. The protocol for this study is available from the authors upon request.

[Table 1](#T0001){ref-type="table"} describes the population, interventions, comparisons, outcomes and study design (PICOS) criteria used to guide the study selection for the NMA. In brief, we included randomized clinical trials (RCTs) assessing the efficacy of any peer-based intervention aimed to improve ART adherence on any HIV population (treatment naive or experienced with or without failure). Outcomes of interest included treatment adherence and viral suppression.

###### 

Population, interventions, comparisons, outcomes and study design (PICOS) criteria for study inclusion

  ---------------------------------------------------------------------------
  Criteria        Definition
  --------------- -----------------------------------------------------------
  Population      People living with HIV on ART

  Interventions   Use of peers to provide adherence support and counselling

  Comparator      Standard of care for ART adherence

  Outcomes        Treatment adherence\
                  Viral suppression

  Study design    Randomized controlled trials
  ---------------------------------------------------------------------------

We conducted a systematic literature search using the following databases from inception to July 2015: Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, Web of Knowledge and WHO Global Index Medicus and trials in progress (International Clinical Trials Registry Platform). In addition, conference abstracts obtained through the EMBASE search, the International AIDS conference (AIDS), the Conference on Retroviruses and Opportunistic Infections and the IAS Conference on HIV Pathogenesis, Treatment and Prevention were searched for the past three years. Hand searches were also performed on the bibliographies of published systematic reviews and health technology assessments. The literature search strategies employed are available in [Supplementary Table 1](#S1){ref-type="supplementary-material"}. Two investigators reviewed all abstracts and proceedings identified in the literature searches. The same two investigators independently reviewed abstracts potentially relevant in full text. If any discrepancies occurred between the studies selected by the two investigators, a third investigator provided arbitration. We excluded non-English studies.

Assessment of study quality {#S0002-S20002}
---------------------------

We assessed risk of bias in the included RCTs using the Cochrane risk-of-bias tool \[[@CIT0010]\] ([Supplementary Table 2](#S1){ref-type="supplementary-material"}). To assess the overall strength of evidence, we employed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for NMA ([Supplementary Tables 3--6](#S1){ref-type="supplementary-material"}) \[[@CIT0011]\]. As a first step, the GRADE system as done in pairwise meta-analyses was applied to direct evidence (i.e. data with head-to-head comparisons); when only indirect evidence existed, we used the NMA estimate and evaluated the shortest indirect pathway with the largest number of trials. For each outcome, the strength of evidence began as high-quality evidence and was rated down if limitations existed due to risk of bias, consistency, directness, imprecision, and/or reporting bias.

Data extraction and variable definitions {#S0002-S20003}
----------------------------------------

Using a standardized data sheet in Microsoft Excel, two investigators independently extracted data on study characteristics, interventions, patient characteristics at baseline and outcomes for the study populations of interest for the final list of selected eligible studies. Any discrepancies observed between the data extracted by the two data extractors were resolved by consensus through discussion.

To improve interpretability and thereby support decision-making, we grouped treatment arms using the following categories: SOC, enhanced standard of care (eSOC), peer supporter, treatment supporter, and telephone ([Table 2](#T0002){ref-type="table"}). eSOC were interventions that provided more support than the usual SOC, and the most frequent extra care was adherence counselling.

###### 

Definitions used for categorization of interventions in the network meta-analysis

  Node                  Description
  --------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SOC                   Usual standard of care
  eSOC                  Enhanced standard of care: SOC+intensified adherence counselling
  Telephone             Interventions that use scripted serial telephone calls or calls, of varying frequencies, to support patients
  CBT                   Cognitive behavioural therapy and cognitive behavioural stress management, as well as interventions that involved counselling with individuals with trained professionals and included interventions that employed motivational interviewing
  Peer supporter        Interventions that involved the use of an individual\'s peers to support treatment adherence. This included home visits, counselling, support and individual or group meetings; this also included directly and modified directly observed therapy
  Treatment supporter   Interventions that involved the use of an individual (chosen by a clinic or patient) to support treatment adherence. This included home visits, treatment assistants and medication managers; this also included directly observed therapy and modified directly observed therapy
  Device reminder       Interventions that involved the use calendars, alarms, pagers or disease management assistance system devices

The primary outcome was adherence, which is defined as the proportion of patients in each RCT arm meeting the trial-defined adherence criteria. The proportion of patients achieving viral suppression, also as defined by the trial, was a secondary outcome. All outcomes were extracted at the end of the study period.

Analyses {#S0002-S20004}
--------

We performed our analyses within the Bayesian framework using hierarchical models. All outcomes were dichotomized and were analyzed by last observed time point. We used a logistic regression model with the logit link function and a binomial likelihood. As heterogeneity was anticipated, we considered both fixed- and random-effects model. Model selection was done using deviance information criterion (DIC), which penalizes for model complexity, and also using leverage plots. The model with the best fit was chosen as the primary analysis model. Estimates of comparative treatment effect were represented as odds ratio (ORs) with associated 95% confidence intervals (95% CI) in pairwise meta-analyses, or 95% credible intervals (95% CrI) in the case of network meta-analyses.

For our meta-regression, the decision whether to use fixed-effects modelling or random-effects modelling was made using the DIC, a measure of model that penalizes for model complexity. In our models, we tried adjusting for the two potential effect modifiers: populations at risk of poor adherence and time discrepancy between outcome and intervention. The populations at risk included intravenous drug users, cocaine and alcohol abusers, people with mental health disorders including severe depression, and people known to be non-adherent; the time discrepancy between outcome and intervention pertained to whether the outcome was measured during the adherence intervention or after the intervention had stopped. In the end, we used unadjusted models because adjusting for neither populations at risk nor the time discrepancy improved the model fit. As sensitivity analysis, we performed analyses using different periods of follow-up (24 and/or 48 weeks). All analyses were performed using R Version 3.1.2 ([www.r-project.org/](http://www.r-project.org/)) and OpenBugs Version 3.23 (OpenBUGS Project Management Group).

Results and discussion {#S0003}
======================

We identified 1696 abstracts from our literature searches; 177 studies underwent full-text review ([Figure 1](#F0001){ref-type="fig"}). In total, 22 trials (24 publications) met the inclusion criteria, and overall they were of moderate quality with low risk of bias. The trial and patient characteristics of the included trials are available in [Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"}.

![Flow chart of study screening.](JIAS-19-21141-g001){#F0001}

###### 

Trial characteristics of the included studies

  Study ID                                               Interventions                    Number randomized   Trial duration (weeks)   Years of trial initiation   Adherence definition                                                                      Viral suppression                                                 LMIC network (Yes/no)   Setting                                                                 Health status of study population   Recruited population details          Age category
  ------------------------------------------------------ -------------------------------- ------------------- ------------------------ --------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------- ----------------------------------------------------------------------- ----------------------------------- ------------------------------------- -------------------------
  ACTG A5073 \[[@CIT0012]\]                              SOC                              161                 48                       2002                        Medication Event Monitoring System (MEMS), 100% adherent                                  Virologic success based on the number of failures at 24 weeks     No                      USA, South Africa                                                       Healthy                             ART-naïve                             Adult
                                                         Treatment supporter              82                                                                                                                                                                                                                                                                                                                                                                                                             
  ACTG a5234 \[[@CIT0013]\]                              SOC                              128                 24                       2009                        MEMS, ≥95% adherent                                                                       \<400 copies/mL at week 48                                        Yes                     Botswana, Brazil, Haiti, Peru, South Africa, Uganda, Zambia, Zimbabwe   Unhealthy                           Treatment failure                     Adult
                                                         Treatment supporter              129                                                                                                                                                                                                                                                                                                                                                                                                            
  Altice *et al*. \[[@CIT0014]\]                         SOC                              53                  24                       2001                        Self-reported, ≥80% adherent                                                              HIV RNA reduction \>1 1.0 log10 or HIV RNA level\<400 copies/mL   No                      USA                                                                     At risk                             Drug users                            Adult
                                                         Treatment supporter              88                                                                                                                                                                                                                                                                                                                                                                                                             
  ATHENA \[[@CIT0015]\]                                  SOC                              84                  60                       1999                        MEMSv, ≥90% adherent                                                                      --                                                                No                      USA                                                                     Healthy                             Treatment experienced                 Adult
                                                         Peer supporter                   87                                                                                                                                                                                                                                                                                                                                                                                                             
  Berrien *et al*. \[[@CIT0016]\]                        SOC                              17                  46                       2000                        Self-reported and pharmacy refill records, continuous                                     VL\<2.6 log                                                       No                      USA                                                                     Healthy                             Treatment experienced                 Adolescent and children
                                                         Treatment supporter              20                                                                                                                                                                                                                                                                                                                                                                                                             
  Goggin *et al*. \[[@CIT0017]\]                         SOC                              65                  48                       2004                        Electronic drug monitoring (EDM), continuous                                              \<400 copies/mL                                                   No                      USA                                                                     Healthy                             Includes some non-adherent patients   Adult
                                                         CBT+Treatment supporter          69                                                                                                                                                                                                                                                                                                                                                                                                             
                                                         CBT                              70                                                                                                                                                                                                                                                                                                                                                                                                             
  Kiweewa *et al*. \[[@CIT0018]\]                        eSOC                             44                  52                       2007                        Pill counts, \>95% adherent                                                               \<400 copies/mL                                                   Yes                     Uganda                                                                  Special population                  Women                                 Adults
                                                         Treatment supporter              48                                                                                                                                                                                                                                                                                                                                                                                                             
  Lucas *et al*. \[[@CIT0019]\]                          SOC                              52                  72                       2006                        Medication Event Monitoring System (MEMS), ≥95% adherent                                  \<50 copies/mL                                                    No                      USA                                                                     At risk                             Drug users                            Adult
                                                         Treatment supporter              55                                                                                                                                                                                                                                                                                                                                                                                                             
  Macalino *et al*. \[[@CIT0020]\]                       SOC                              43                  48                       2001                        Self-reported, adherent was not missing 1 dose in prior month                             \<50 copies/mL                                                    No                      USA                                                                     At risk                             Drug users                            Adult
                                                         Treatment supporter              44                                                                                                                                                                                                                                                                                                                                                                                                             
  Mugusi *et al*. \[[@CIT0021]\]                         CBT+Device reminder              242                 72                       2004                        Self-reported "Did not miss taking ARVs"                                                  --                                                                Yes                     Tanzania                                                                Healthy                             ART-naïve                             Adult
                                                         CBT+Peer supporter               67                                                                                                                                                                                                                                                                                                                                                                                                             
                                                         eSOC                             312                                                                                                                                                                                                                                                                                                                                                                                                            
  Nachega *et al*. \[[@CIT0022]\]                        SOC                              137                 48                       2005                        **Pill counts**                                                                           \<400 copies/mL                                                   Yes                     South Africa                                                            Healthy                             ART-naïve                             Adult
                                                         Treatment supporter              137                                                                                                                                                                                                                                                                                                                                                                                                            
  Pearson *et al*. \[[@CIT0023]\]                        eSOC                             175                 52                       2004                        Self-reported, 7-day recall                                                               --                                                                Yes                     Mozambique                                                              Healthy                             ART-naïve                             Adult
                                                         Peer supporter                   125                                                                                                                                                                                                                                                                                                                                                                                                            
  Rakai Health Sciences Program \[[@CIT0024]\]           SOC                              366                 192                      2006                        Medication Event Monitoring System (MEMS) and pill counts, \>95% adherent                 \<400 copies/mL                                                   Yes                     Uganda                                                                  Healthy                             Treatment naïve and experienced       Adult
                                                         Peer supporter                   970                                                                                                                                                                                                                                                                                                                                                                                                            
  Remien *et al*. \[[@CIT0025]\] (SMART Couples Study)   SOC                              109                 24                       2000                        Medication Event Monitoring System (MEMS)                                                 --                                                                No                      USA                                                                     Healthy                             Treatment naïve and experienced       Adult
                                                         Peer supporter                   106                                                                                                                                                                                                                                                                                                                                                                                                            
  Ruiz *et al*. \[[@CIT0026]\]                           Peer supporter                   120                 24                       2003                        Self-reported, SMAQ questionnaire, adherent if missed less than 2 doses in three months   \<50 copies/mL                                                    No                      Spain                                                                   Healthy                             Treatment experienced                 Adults
                                                         CBT                              120                                                                                                                                                                                                                                                                                                                                                                                                            
  Simoni *et al*. \[[@CIT0027]\]                         SOC                              64                  12                       2000                        Self-reported                                                                             --                                                                No                      USA                                                                     At risk                             Poor                                  Adults
                                                         Peer supporter                   71                                                                                                                                                                                                                                                                                                                                                                                                             
  Simoni *et al*. \[[@CIT0028]\]                         SOC                              57                  24                       2003                        Self-Report, 100% adherent                                                                \< 1000 copies/ml at all three follow-up assessments              No                      USA                                                                     Healthy                             Treatment naïve and experienced       Adults
                                                         Device reminder                  57                                                                                                                                                                                                                                                                                                                                                                                                             
                                                         Peer supporter+Device reminder   56                                                                                                                                                                                                                                                                                                                                                                                                             
                                                         Peer supporter                   56                                                                                                                                                                                                                                                                                                                                                                                                             
  START-DOT \[[@CIT0029]\]                               SOC                              38                  24                       2007                        Self-reported, 100% adherent                                                              \<75 copies/mL                                                    No                      USA                                                                     At risk                             IDU                                   Adult
                                                         Treatment supporter              39                                                                                                                                                                                                                                                                                                                                                                                                             
  Taiwo *et al*. \[[@CIT0030]\]                          SOC                              251                 48                       2006                        Self-reported, ≥95% adherent                                                              \<75 copies/mL                                                    Yes                     Nigeria                                                                 Healthy                             ART-naïve                             Adult
                                                         Treatment supporter              248                                                                                                                                                                                                                                                                                                                                                                                                            
  Wang *et al*. \[[@CIT0031]\]                           SOC                              58                  32                       2007                        Self-reported, 100% adherent                                                              --                                                                Yes                     China                                                                   At risk                             IDU                                   Adults
                                                         Treatment supporter+Telephone    58                                                                                                                                                                                                                                                                                                                                                                                                             
  Williams *et al*. \[[@CIT0032]\]                       SOC                              55                  52                       2010                        Self-reported                                                                             \<400 copies/mL                                                   Yes                     China                                                                   At risk                             Non-adherent, Depression symptoms     Adults
                                                         Peer supporter+Telephone         55                                                                                                                                                                                                                                                                                                                                                                                                             
  Wohl *et al*. \[[@CIT0033]\]                           SOC                              84                  24                       2001                        Self-reported, recall 7 days prior                                                        \<400 copies/mL                                                   No                      USA                                                                     Healthy                             Treatment naïve and experienced       Adults
                                                         Treatment supporter              82                                                                                                                                                                                                                                                                                                                                                                                                             

All of the trials included evaluated patients in the adult age category. SOC, standard-of-care; eSOC, enhanced SOC; CBT, cognitive behavioural therapy; IDU, intravenous drug users.

###### 

Patient characteristics of the included trials

  Study ID                                               Interventions                    Mean age                                Males -- *n* (%)   AIDS-defining illness -- *n* (%)   Baseline CD4 (cells/mm^3^) mean        Baseline viral load (log copies/mL) mean   Men who have sex w/ men -- *n* (%)   Persons who inject drugs -- *n* (%)
  ------------------------------------------------------ -------------------------------- --------------------------------------- ------------------ ---------------------------------- -------------------------------------- ------------------------------------------ ------------------------------------ -------------------------------------
  ACTG A5073 \[[@CIT0012]\]                              SOC                              39.3                                    127 (79)           --                                 233                                    4.8                                        --                                   18 (12)
                                                         Supporter                        38                                      65 (79)            --                                 212                                    5                                          --                                   10 (12)
  ACTG a5234 \[[@CIT0013]\]                              SOC                              37[a](#TF0001){ref-type="table-fn"}     63 (49)            --                                 201[a](#TF0001){ref-type="table-fn"}   4.3[a](#TF0001){ref-type="table-fn"}       --                                   --
                                                         Supporter                        38[a](#TF0001){ref-type="table-fn"}     67 (52)            --                                 164[a](#TF0001){ref-type="table-fn"}   4.2[a](#TF0001){ref-type="table-fn"}       --                                   --
  Altice *et al*. \[[@CIT0014]\]                         SOC                              44.9[a](#TF0001){ref-type="table-fn"}   37 (69.8)          --                                 384[a](#TF0001){ref-type="table-fn"}   2.8[a](#TF0001){ref-type="table-fn"}       --                                   35 (66)
                                                         Treatment supporter              42.7[a](#TF0001){ref-type="table-fn"}   60 (68.2)          --                                 283[a](#TF0001){ref-type="table-fn"}   3.8[a](#TF0001){ref-type="table-fn"}       --                                   57 (64.8)
  ATHENA \[[@CIT0015]\]                                  SOC                              --                                      40 (48)            --                                 415                                    4.47                                       --                                   6 (8)
                                                         Peer supporter                   --                                      48 (55)            --                                 445                                    4.46                                       --                                   3 (4)
  Berrien *et al*. \[[@CIT0016]\]                        SOC                              11.2                                    9 (55)             --                                 860.8                                  3.92                                       --                                   --
                                                         Treatment supporter              9.9                                     9 (45)             --                                 838.6                                  3.67                                       --                                   --
                                                         SOC                              36                                      19 (54.3)          --                                 194                                    5.75                                       2                                    --
  Goggin *et al*. \[[@CIT0017]\]                         CBT+Treatment supporter          40.4                                    50 (76.9)          --                                 --                                     4.2[a](#TF0001){ref-type="table-fn"}       --                                   29 (42)
                                                         CBT                              40.8                                    50 (71.4)          --                                 --                                     4.3[a](#TF0001){ref-type="table-fn"}       --                                   30 (43.5)
                                                         eSOC                             39.9                                    55 (79.7)          --                                 --                                     5                                          --                                   29 (44.6)
  Kiweewa *et al*. \[[@CIT0018]\]                        Treatment supporter              27.8                                    0 (0)              --                                 204[a](#TF0001){ref-type="table-fn"}   4.5[a](#TF0001){ref-type="table-fn"}       --                                   --
                                                         SOC                              27                                      0 (0)              --                                 201[a](#TF0001){ref-type="table-fn"}   4.8[a](#TF0001){ref-type="table-fn"}       --                                   --
  Lucas *et al*. \[[@CIT0019]\]                          Treatment supporter              47[a](#TF0001){ref-type="table-fn"}     25 (48)            --                                 --                                     4.97                                       --                                   26 (50)
                                                         SOC                              47[a](#TF0001){ref-type="table-fn"}     31 (56)            --                                 --                                     4.78                                       --                                   22 (40)
  Macalino *et al*. \[[@CIT0020]\]                       Treatment supporter              41.7                                    34 (79)            --                                 --                                     --                                         --                                   33 (76.7)
                                                         SOC                              43.1                                    27 (61)            --                                 --                                     --                                         --                                   39 (88.6)
  Mugusi *et al*. \[[@CIT0021]\]                         eSOC                             39.9                                    96 (31)            7 (2.3)                            98.1                                   --                                         --                                   --
                                                         Supporter                        --                                      0 (0)              --                                 --                                     --                                         --                                   --
                                                         CBT+Device reminder              39.5                                    94 (39)            6 (2.5)                            97.7                                   --                                         --                                   --
                                                         CBT+Peer supporter               37.8                                    28 (42)            2 (3)                              91.1                                   --                                         --                                   --
  Nachega *et al*. \[[@CIT0022]\]                        SOC                              36.7                                    58 (42.3)          61 (44.5)                          103[a](#TF0001){ref-type="table-fn"}   5[a](#TF0001){ref-type="table-fn"}         --                                   --
                                                         Treatment supporter              35.7                                    58 (42.3)          65 (47.4)                          92[a](#TF0001){ref-type="table-fn"}    5[a](#TF0001){ref-type="table-fn"}         --                                   --
  Pearson *et al*. \[[@CIT0023]\]                        eSOC                             36.1                                    82 (46.9)          --                                 --                                     --                                         --                                   --
                                                         Peer supporter                   35.6                                    80 (45.7)          --                                 --                                     --                                         --                                   --
  Rakai Health Sciences Program \[[@CIT0024]\]           SOC                              34[a](#TF0001){ref-type="table-fn"}     119 (32.5)         --                                 161[a](#TF0001){ref-type="table-fn"}   --                                         --                                   --
                                                         Peer supporter                   35.5[a](#TF0001){ref-type="table-fn"}   332 (34.2)         --                                 160[a](#TF0001){ref-type="table-fn"}   --                                         --                                   --
  Remien *et al*. \[[@CIT0025]\] (SMART Couples Study)   SOC                              --                                      --                 --                                 --                                     4.05                                       --                                   --
                                                         Peer supporter                   --                                      --                 --                                 --                                     4.20                                       --                                   --
  Ruiz *et al*. \[[@CIT0026]\]                           Peer supporter                   41.32                                   81 (67.5)          --                                 471                                    --                                         33 (28)                              51 (42.5)
                                                         CBT                              41                                      95 (79)            --                                 486                                    --                                         24 (20.5)                            59 (49.2)
  Simoni *et al*. \[[@CIT0027]\]                         SOC                              42.5                                    40 (62.5)          --                                 --                                     8.4                                        --                                   35 (53.8)
                                                         Peer supporter                   42.6                                    35 (49.3)          --                                 --                                     8                                          --                                   35 (49.3)
  Simoni *et al*. \[[@CIT0028]\]                         SOC                              --                                      --                 --                                 198.5                                  4.3                                        --                                   --
                                                         Peer supporter                   --                                      --                 --                                 195.4                                  4.3                                        --                                   --
                                                         Device reminder                  --                                      --                 --                                 229.2                                  4.6                                        --                                   --
                                                         Peer supporter+Device reminder   --                                      --                 --                                 194.3                                  4.5                                        --                                   --
  START-DOT \[[@CIT0029]\]                               SOC                              49                                      22 (58)            --                                 277[a](#TF0001){ref-type="table-fn"}   2.89                                       --                                   --
                                                         Treatment supporter              45                                      19 (49)            --                                 367[a](#TF0001){ref-type="table-fn"}   2.74                                       --                                   --
  Taiwo *et al*. \[[@CIT0030]\]                          SOC                              --                                      83 (33.5)          --                                 107.6                                  4.82[a](#TF0001){ref-type="table-fn"}      --                                   --
                                                         Treatment supporter              --                                      91 (36.3)          --                                 106.1                                  4.78[a](#TF0001){ref-type="table-fn"}      --                                   --
  Wang *et al*. \[[@CIT0031]\]                           SOC                              36.7                                    49 (84)            --                                 --                                     --                                         --                                   58 (100)
                                                         Treatment supporter+Telephone    36.7                                    49 (84)            --                                 --                                     --                                         --                                   58 (100)
  Williams *et al*. \[[@CIT0032]\]                       SOC                              37                                      42 (76.4)          --                                 137                                    --                                         --                                   21 (38.2)
                                                         Peer supporter+Telephone         38                                      36 (65.5)          --                                 149                                    --                                         --                                   14 (25.5)
  Wohl *et al*. \[[@CIT0033]\]                           SOC                              --                                      66 (78.6)          --                                 143[a](#TF0001){ref-type="table-fn"}   4.2[a](#TF0001){ref-type="table-fn"}       29 (34.5)                            4 (4.8)
                                                         Treatment supporter              --                                      59 (72)            --                                 105[a](#TF0001){ref-type="table-fn"}   4.6[a](#TF0001){ref-type="table-fn"}       25 (30.5)                            5 (6.1)

Median value reported.

Our exploratory analysis suggested the choice of the threshold used to define adherence and viral suppression was not an effect modifier, and we therefore pooled data for adherence and viral suppression across studies despite varying definitions. The most common definitions used for adherence were \>95 and 100% adherence, and the most common definitions used for viral suppression were \<400 and \<50 copies/mL.

Our primary network, the global network, included 20 trials (3902 patients randomized to 42 intervention arms) that reported ART adherence and 17 trials (3147 patients randomized to 36 intervention arms) that reported viral suppression. Our secondary network, which consisted of trials done in low- and middle-income countries (LMICs), included eight trials (2467 patients randomized to 16 intervention arms) that reported ART adherence and six trials (1678 patients randomized to 12 intervention arms) that reported viral suppression. The network diagram of trials included in the global adherence network is provided in [Figure 2](#F0002){ref-type="fig"}. The primary network diagram for viral suppression and LMIC network diagrams are provided in [Supplementary Figures 1, 2 and 3](#S1){ref-type="supplementary-material"}).

![Network diagram of the 20 trials included in the global peer adherence network. Each node (circle) represents an intervention, each line represents a direct comparison between interventions and each number on the lines represents the number of trials with the comparison in question. Orange circles represent counselling-based interventions, pink circles represent supporter-based interventions and blue circles represent all other interventions.\
CBT, cognitive behavioural therapy; eSOC, enhanced standard of care; SOC, standard of care](JIAS-19-21141-g002){#F0002}

We used random effects models for the analysis of global network. The results of pairwise meta-analysis and the NMA were similar ([Figure 3](#F0003){ref-type="fig"}). Peer supporter+Telephone was superior in improving adherence than SOC (OR: 4.87, 95% CrI: 1.02, 23.76) ([Table 5](#T0005){ref-type="table"}). Treatment supporter+Telephone performed better than all interventions in the network. However, the effects of Treatment supporter+Telephone are unreliable, as this node only connected with the SOC node with a single trial \[[@CIT0031]\] of 98 patients at high risk of poor adherence (i.e. intravenous drug users); this limited connection likely influenced the results. For viral suppression, due to limited trials, we found no difference of effects on viral suppression among interventions in the global network ([Supplementary Table 8](#S1){ref-type="supplementary-material"}).

![Forest plot displaying the association between different peer-based adherence interventions with treatment adherence and viral suppression outcomes: Global Peer Network.](JIAS-19-21141-g003){#F0003}

###### 

Cross-table of random effects network meta-analysis for global peer adherence network

  ------------------------- -------------------------- -------------------------- ------------------------ ----------------------------- ------------------------- ------------------------------------ ------------------------------ ------------------------- -----------------------------------
  **SOC**                   1.47 (0.38, 5.93)          1.23 (0.42, 3.57)          0.96 (0.07, 10.01)       1.62 (0.41, 6.30)             0.97 (0.52, 1.81)         0.77 (0.21, 2.86)                    **0.21 (0.04, 0.98)**          0.66 (0.36, 1.09)         **0.09 (0.01, 0.54)**
  0.68 (0.17, 2.63)         **eSOC**                   0.83 (0.16, 4.26)          0.67 (0.07, 4.20)        1.10 (0.16, 7.18)             0.66 (0.18, 2.34)         0.52 (0.08, 3.17)                    0.14 (0.02, 1.10)              0.45 (0.10, 1.77)         **0.06 (0.01, 0.59)**
  0.82 (0.28, 2.40)         1.21 (0.24, 6.35)          **CBT**                    0.79 (0.05, 9.57)        1.32 (0.34, 5.12)             0.79 (0.27, 2.33)         0.63 (0.12, 3.22)                    0.17 (0.02, 1.13)              0.54 (0.15, 1.69)         **0.08 (0.01, 0.61)**
  1.04 (0.10, 13.77)        1.50 (0.24, 13.98)         1.27 (0.10, 19.64)         **CBT+Peer supporter**   1.68 (0.11, 30.31)            1.00 (0.10, 12.81)        0.80 (0.06, 13.88)                   0.21 (0.01, 4.36)              0.68 (0.06, 9.07)         0.10 (0.00, 2.19)
  0.62 (0.16, 2.42)         0.91 (0.14, 6.22)          0.76 (0.20, 2.93)          0.60 (0.03, 8.73)        **CBT+Treatment supporter**   0.60 (0.14, 2.51)         0.48 (0.07, 3.09)                    0.13 (0.02, 1.01)              0.41 (0.09, 1.67)         **0.06 (0.01, 0.53)**
  1.03 (0.55, 1.94)         1.52 (0.43, 5.57)          1.26 (0.43, 3.69)          1.00 (0.08, 9.66)        1.67 (0.40, 6.94)             **Peer supporter**        0.80 (0.21, 2.96)                    0.21 (0.04, 1.15)              0.68 (0.28, 1.48)         **0.10 (0.01, 0.62)**
  1.29 (0.35, 4.83)         1.91 (0.32, 11.85)         1.58 (0.31, 8.10)          1.25 (0.07, 16.95)       2.10 (0.32, 13.47)            1.26 (0.34, 4.72)         **Peer supporter+Device reminder**   0.26 (0.03, 2.03)              0.85 (0.20, 3.36)         0.12 (0.01, 1.10)
  **4.87 (1.02, 23.76)**    7.15 (0.91, 58.16)         5.93 (0.89, 40.10)         4.67 (0.23, 78.03)       7.87 (0.99, 62.76)            4.73 (0.87, 25.66)        3.78 (0.49, 29.34)                   **Peer supporter+Telephone**   3.22 (0.57, 16.40)        0.45 (0.04, 4.93)
  1.51 (0.92, 2.79)         2.22 (0.57, 10.28)         1.84 (0.59, 6.46)          1.47 (0.11, 16.75)       2.45 (0.60, 11.20)            1.47 (0.68, 3.53)         1.17 (0.30, 5.08)                    0.31 (0.06, 1.75)              **Treatment supporter**   **0.14 (0.02, 0.93)**
  **10.69 (1.86, 74.00)**   **15.88 (1.70, 168.30)**   **13.21 (1.65, 117.10)**   10.33 (0.46, 220.20)     **17.53 (1.88, 177.60)**      **10.43 (1.61, 78.37)**   8.27 (0.91, 86.86)                   2.21 (0.20, 25.90)             **7.08 (1.07, 50.17)**    **Treatment supporter+Telephone**
  ------------------------- -------------------------- -------------------------- ------------------------ ----------------------------- ------------------------- ------------------------------------ ------------------------------ ------------------------- -----------------------------------

Each cell represents the estimated comparative effect (odds ratio and 95% credible interval). In the cells below the diagonal, the ORs show comparative effects of the row interventions relative to the column treatment (e.g. the effect of SOC relative to eSOC is 0.68 with respect to adherence). In the cells above the diagonal, the ORs show comparative effects of the column interventions relative to the row treatment (e.g. the effect of eSOC relative to SOC is 1.47 with respect to adherence). Bold values indicate comparisons that are statistically significant. ORs above 1 indicate higher efficacy in adherence.

OR, odds ratio; CBT, cognitive behavioural therapy; eSOC, enhanced standard of care; SOC, standard of care.

The comparative results on ART adherence were mostly similar between the global and LMIC networks. In the LMIC network, the results of pairwise meta-analysis, where direct evidence was available, were similar to that of the NMA ([Figure 4](#F0004){ref-type="fig"}). Peer supporter+Telephone was superior in improving adherence than SOC (OR: 4.83, 95% CrI: 1.88, 13.55) and eSOC (OR: 4.35, 95% CrI: 1.07, 19.01). Peer supporter+Telephone also performed better than Treatment supporter (OR: 3.43, 95% CrI: 1.21, 10.60) ([Supplementary Table 8](#S1){ref-type="supplementary-material"}). Treatment supporter+Telephone showed superior effects in comparison to all other interventions. However, again due to the same single trial \[[@CIT0031]\] connected to SOC, the found effects are not reliable.

![Forest plot displaying the association between different peer-based adherence interventions with treatment adherence and viral suppression outcomes: LMIC Peer Network.](JIAS-19-21141-g004){#F0004}

The comparative results of viral suppression among LMIC trials are presented in [Supplementary Table 9](#S1){ref-type="supplementary-material"}. Again, due to limited LMIC trials reporting on viral suppression, we found no difference of effects on viral suppression between interventions in the LMIC network. The sensitivity analyses restricting to studies reporting ART adherence at 24 and 48 weeks are presented in [Supplementary Tables 10 and 11](#S1){ref-type="supplementary-material"}, and the results for viral suppression at 48 weeks are presented in [Supplementary Table 12](#S1){ref-type="supplementary-material"}. The results of the sensitivity analyses were relatively consistent with the overall network.

In this NMA, we compared the effects of peer-based interventions targeted to improve ART adherence assessed among randomized trials, both worldwide and restricted to LMIC settings. Our findings demonstrate that providing peer support in combination with other interventions offers modest improvement in adherence over the standard care in both the global and LMIC settings. However, peer support alone did not show any improvement, and we found no difference of effects among peer-based interventions on viral suppression due to limited trials. This analysis may dampen enthusiasm towards peer-supported interventions.

We separately performed an additional NMA that assessed the effectiveness of non-peer-based interventions to inform the new global consolidated guidelines for the WHO \[[@CIT0008]\]. In that NMA of non-peer interventions, we found that interventions based on supportive strategies, such as two-way text messaging and counselling, offer improved adherence over low-support interventions and reminder systems that are typical in SOC. These findings were consistent to prior reviews which showed that provision of support, rather than therapies involving direct observations, appears to be more consistently effective \[[@CIT0034]\]. This systematic review of peer-based interventions, on the other hand, showed that peer support alone did not lead to improvement in ART adherence. This may likely be due to the fact that in many settings, particularly in LMICs, programmes already include treatment supporters via peer supporters, adherence clubs, and family disclosures. Rather than introducing new interventions, a focus on improving the quality in the delivery of existing services may be a more practical and effective way to improve adherence to ART.

Our study has its strengths and limitations. The main strength of our study lies in the application of an NMA approach because NMA allows for a broad assessment of the effectiveness of different interventions. However, the existing evidence base limited our study. There were limited trials evaluating peer-based interventions, and this was especially problematic for the viral suppression outcome. Another limitation of the study was our categorization of interventions; we combined interventions into broad categories to assist with interpretation. There were no statistical heterogeneities in the combined categories, so it is unlikely that our categorization introduced significant bias in our analysis. However, we acknowledge that a different approach to categorization may alter the results. Moreover, there was notable variation in the assessment methods (e.g. use of medication event monitoring system, self-reporting and pill counts) in our study outcome of ART adherence. This was not shown as an effect modifier, but these inconsistent measurements may have had introduced heterogeneity in our analyses. Finally, we acknowledge the heterogeneity within the trials in our evidence base (e.g. treatment experienced vs. naïve patients and automated vs. personal form of counselling). There is evidence that many of these differences would affect the validity of our findings \[[@CIT0035]\]; however, it was not possible to stratify or control for these differences due to the limited number of trials.

This review identified several directions for future research. Adherence to ART is a lifelong requirement; yet, there is an important paucity of information on promoting adherence within populations that have been receiving ART for long periods of time. As the barriers to adherence are complex and change over time \[[@CIT0036]\], there is a clear need to maintain and evaluate adherence interventions over the long term. We found there is a lack of high-quality research to support adolescents and paediatric HIV populations transition into their adulthood There is also a need to better identify those individuals who are at risk of poor adherence \[[@CIT0037]\]. Moreover, there is a need to standardize outcome measures in adherence and viral suppression for adherence intervention research, to improve comparability of studies and, consequently, the formulation of policy recommendations.

Previous WHO guideline focused narrowly on promoting the use of text messaging to improve adherence, based on data from simple and robust trials demonstrating efficacy \[[@CIT0038]\]. Based on the findings of our reviews, WHO has recently expanded its recommendations for adherence support, recommending a series of options that include peer counsellors, text messages, reminder devices, cognitive behavioural therapy, behavioural skills training and medication adherence training \[[@CIT0008]\]. WHO now recognizes that nutritional and financial support may be of value in addressing specific challenges that impact adherence.

Global HIV targets include a goal of achieving 90% virological suppression among people on ART \[[@CIT0039]\]. Consequently, there is a renewed focus on the need to improve adherence to ART. As the latest WHO guidelines are adopted, HIV programmes may consider adopting or adapting these interventions according to desired programme outcomes, resource availability and other socio-economic contextual factors, especially when scaling up to a national level; this provides an important opportunity to evaluate the benefits of these interventions in routine practice. This, in turn, will generate new evidence that, together with the outcomes of ongoing trials, will support an increasingly nuanced evidence-based approach to supporting adherence for the 37 million people who are now considered eligible to receive ART.

Conclusions {#S0004}
===========

Adherence to ART is a lifelong requirement, with a critical need to maintain and evaluate adherence interventions over long term. This study demonstrates that peer support may lead to modest improvement in adherence. We may only have observed modest effects since in many settings programmes already include peer supporters, adherence clubs and family disclosures for treatment support. Future efforts should be focused on improving the quality in the delivery of existing services, which may be a more practical and effective way to improve adherence to ART.
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